Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Total Current Liabilities (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Total Current Liabilities data on record, last reported at $8.1 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities fell 82.6% year-over-year to $8.1 million; the TTM value through Sep 2025 reached $8.1 million, down 82.6%, while the annual FY2024 figure was $35.4 million, 415.39% up from the prior year.
  • Total Current Liabilities reached $8.1 million in Q3 2025 per CRVS's latest filing, down from $8.5 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $46.4 million in Q3 2024 and bottomed at $6.7 million in Q1 2024.
  • Average Total Current Liabilities over 4 years is $13.5 million, with a median of $9.3 million recorded in 2022.
  • Peak YoY movement for Total Current Liabilities: surged 535.79% in 2024, then plummeted 82.6% in 2025.
  • A 4-year view of Total Current Liabilities shows it stood at $10.8 million in 2022, then crashed by 36.11% to $6.9 million in 2023, then soared by 415.39% to $35.4 million in 2024, then crashed by 77.19% to $8.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $8.1 million in Q3 2025, $8.5 million in Q2 2025, and $9.3 million in Q1 2025.